This company listing is no longer active
ENDPQ N Stock Overview
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Endo International plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$169.00 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 1.59 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | 39.67% |
| 5 Year Change | 27.40% |
| Change since IPO | 45.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| ENDPQ N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | 1.9% | 2.4% |
| 1Y | n/a | -16.8% | 2.7% |
Return vs Industry: Insufficient data to determine how ENDPQ N performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ENDPQ N performed against the MX Market.
Price Volatility
| ENDPQ N volatility | |
|---|---|
| ENDPQ N Average Weekly Movement | 0% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in MX Market | 6.1% |
| 10% least volatile stocks in MX Market | 1.9% |
Stable Share Price: ENDPQ N has not had significant price volatility in the past 3 months.
Volatility Over Time: ENDPQ N's weekly volatility (0%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1920 | 3,103 | Blaise Coleman | www.endo.com |
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren’s contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company’s Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections.
Endo International plc Fundamentals Summary
| ENDPQ N fundamental statistics | |
|---|---|
| Market cap | Mex$347.86m |
| Earnings (TTM) | -Mex$58.31b |
| Revenue (TTM) | Mex$46.21b |
0.0x
P/S Ratio0.0x
P/E RatioIs ENDPQ N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENDPQ N income statement (TTM) | |
|---|---|
| Revenue | US$2.55b |
| Cost of Revenue | US$1.09b |
| Gross Profit | US$1.47b |
| Other Expenses | US$4.69b |
| Earnings | -US$3.22b |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -13.70 |
| Gross Margin | 57.42% |
| Net Profit Margin | -126.20% |
| Debt/Equity Ratio | -203.3% |
How did ENDPQ N perform over the long term?
See historical performance and comparison